Title: Profile of COPD Patients in Rural Population Attending Rural Tertiary Health Care Centre of Central India
Authors: Ranjit Kumar Nim, Vivek Kumar Verma, Premshanker Singh, Manoj Kumar, Dheeraj Kela, Geeta Singh, Sushil Kumar, Anand Kumar Singh
DOI: https://dx.doi.org/10.18535/jmscr/v5i5.118
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a major worldwide health problem that has an increasing prevalence and mortality. Exacerbations and co-morbidities contribute to the overall severity in individual patients. Although COPD is a lung disease, it is associated with systemic manifest-ations and co-morbid conditions. So assessment of various co-morbidities and early intervention can cause decrease in hospital stay, improvement in quality of life and decrease mortality, in COPD patients.
Aim: To study the prevalence of various co-morbidities in patients of COPD in rural population.
Methods: A cross sectional study was conducted on 48 patients in UPUMS Saifai attending department of medicine between October 2016 to March 2017.Various co-morbidities were assessed by clinical, haematological, biochemical and radiologically
Results: In our study we found that all the patients included had at least one co-morbid condition. 30% patients were having 3 co-morbid condition and 16% patients were suffering from 4 co-morbid conditions.
Conclusion: Patients with higher GOLD groups had more number of co-morbid conditions. Early detection and treatment of various co-morbid conditions is required so that there will be decrease mortality and hospital stay as well as improve quality of life.
References
1. Bousquet J, Kiley J, Bateman ED, et al. Prioritized research agenda for prevention and control of chronic respiratory diseases. Eur Respir J 2010;36:995–1001.
2. Lopez AD, Mathers CD. Measuring the global burden of disease and epidemiological transitions: 2002-2030. Ann Trop Med Parasitol 2006;100:481–99. Respir J 2010;36:718–9.
3. Lopez AD, Mathers CD, Ezzati M, et al, editors. Global burden of disease and risk factors. Washington, DC: World Bank Publications; 2006. p. 1–11. Chapter 1.
4. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532–55.
5. Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, Ligabue G, Ciaccia A, Saetta M, Papi A. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167(3):418–424.
6. Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randmoized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-contro-lled trial. Lancet 2005; 365:1552–1560.
7. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in chronic obstructive pulmonary disease. EurRespir J 2008; 32: 962–269.
8. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005–1012.
9. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in chronic obstructive pulmonary disease. EurRespir J 2008; 32: 962–269.
10. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. EurRespir J 2009; 33: 1165–1185
11. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28:523–32.
12. Blanc PD, Iribarren C, Trupin L, et al. Occupational exposures and the risk of COPD: dusty trades revisited. Thorax 2009;64:6–12.
13. Cote CG, Pinto-Plata VM, Marin JM, Nekach H, Dordelly LJ, Celli BR. The modified BODE index: validation with mortality in COPD. Eur Respir J 2008;32:1269–1274.
14. Kerry Schnell, Carlos O Weiss et al. prevalence of clinicaly relevant comorbid conditions in patient with physician –diagnosed COPD)BMC Pulm Med2012: 12(26).
15. Elwing J1, PanosRJInt J Chron Obstruct Pulmon Dis. 2008;3(1):55-70.Pulmonary hypertension associated with COPD.
16. Peter Lange, Rasmus Mogelvang, Jacob Louis Marott, Jøørgen Vestbo, and Jan Skov Jensen1. Cardiovascular Morbidity in COPD: A Study of the General Population JOURNAL OF COPD February 2010, Vol. 7, No. 1 , Pages 5-10.
17. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB.Health care utilization in chronic obstructive pulmonary disease: acase-control study in a health maintenance organization. Arch InternMed 2000;160:2653–2658.